Background/Aims: Malignant pleural mesothelioma (MPM) is an aggressive malignant tumor and an effective therapy has been little provided as yet. The present study investigated the possibility for the adenosine deaminase (ADA) inhibitor EHNA as a target of MPM treatment. Methods: MTT assay, TUNEL staining, monitoring of intracellular adenosine concentrations, and Western blotting were carried out in cultured human MPM cell lines without and with knocking-down ADA. The in vivo effect of EHNA was assessed in mice inoculated with NCI-H2052 MPM cells. Results: EHNA induced apoptosis of human MPM cell lines in a concentration (0.01-1 mM)-and treatment time (24-48 h)-dependent manner, but such effect was not obtained with another ADA inhibitor pentostatin. EHNA increased intracellular adenosine concentrations in a treatment time (3-9 h)-dependent manner. EHNA-induced apoptosis of MPM cells was mimicked by knocking-down ADA, and the effect was neutralized by the adenosine kinase inhibitor ABT-702. EHNA clearly suppressed tumor growth in mice inoculated with NCI-H2052 MPM cells. Conclusion: The results of the present study show that EHNA induces apoptosis of MPM cells by increasing intracellular adenosine concentrations, to convert to AMP, and effectively prevents MPM cell proliferation. This suggests that EHNA may be useful for treatment of the tragic neoplasm MPM.
Introduction
Malignant pleural mesothelioma (MPM), a highly aggressive neoplasm, has been increasing in incidence globally [1] . Previous exposure to asbestos ibers essentially contributes to the pathogenesis of MPM, which is characterized by insidious growth and chemotherapy resistance with poor prognosis. In spite of extensive and intensive challenges, MPM therapy has been still limited to marginally effective chemotherapy and morbid surgery.
Accumulating evidence has pointed to adenosine-induced apoptosis in a variety of cancer cells, largely as mediated through intrinsic and/or extrinsic pathways. For the intrinsic pathway, extracellular adenosine is taken into cells by adenosine transporters and converted to AMP by adenosine kinase to activate AMP-activated protein kinase (AMPK), responsible for apoptosis in GT3-TKB human lung cancer cells and HuH-7 human hepatoma cells [2, 3] . Intracellularly transported adenosine also induces apoptosis in a caspase-dependent or -independent manner in HuH-7, HepG2 human hepatocellular carcinoma, MCF-7 human breast cancer, or human MPM cells [3] [4] [5] [6] [7] [8] . For the extrinsic pathway, adenosine receptors, which include A 1 , A 2a , A 2b , and A 3 receptors, mediate apoptosis. Adenosine induces apoptosis in CW2 human colonic cancer cells and RCR-1 rat astrocytoma cells via A 1 adenosine receptor [9, 10] . Adenosine induces apoptosis in Caco-2 human colonic cancer and HepG2 cells via A 2a adenosine receptor [11, 12] . A 3 adenosine receptor mediates apoptosis in human lung cancer cells, hepatocellular carcinoma cells, thyroid cancer cells, breast cancer cells, renal cancer cells, bladder cancer cells, and MPM cells by the diverse independent mechanisms [13] [14] [15] [16] [17] [18] [19] [20] .
Adenosine is broken down into inosine by adenosine deaminase (ADA). ADA inhibition should raise adenosine concentrations by preventing adenosine breakdown. Then, we postulated that the ADA inhibitor erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA) could exert its antitumor action against a variety of cancers. We show here that EHNA has the potential to induce apoptosis of MPM cells and suppress tumor growth in mice inoculated with NCI-H2052 cells.
Materials and Methods

Cell culture
Human MPM cell lines such as NCI-H28, NCI-H2052, NCI-H2452, and MSTO-211H cells were purchased from American Type Culture Collection (Manassas, VA, USA). Cells were grown in RPMI-1640 medium supplemented with 10% heat-inactivated fetal bovine serum (FBS), 0.003% L-glutamine, penicillin ( inal concentration, 100 U/ml), and streptomycin ( inal concentration, 0.1 mg/ml). Human lung cancer cell lines A549, SBC-3, and Lu-65 cells were purchased from Health Science Research Resources Bank (Osaka, Japan). A549 and SBC-3 cells were grown in minimum essential medium (MEM) containing 0.1 mM non-essential amino acids and Lu-65 cells in RPMI-1640 medium supplemented with 10% (v/v) heat-inactivated FBS, penicillin ( inal concentration, 100 U/ml) and streptomycin ( inal concentration, 0.1 mg/ml). Human hepatic cancer cell lines HepG2 and HuH-7 cells, obtained from RIKEN cell bank (Ibaraki, Japan), were cultured in Dulbecco's Modi ied Eagles Medium (DMEM) supplemented with 10% (v/v) heat-inactivated FBS, penicillin ( inal concentration, 100 U/ml) and streptomycin ( inal concentration, 0.1 mg/ml). All the cells were incubated in a humidi ied atmosphere of 5% CO 2 and 95% air at 37 °C.
Western blotting
Cells transfected with the ADA siRNA or the NC siRNA were lysed in lysis buffer [150 mM NaCl, 20 mM EDTA, 0.5% (v/v) Nonidet P-40 and 50 mM Tris, pH 7.4] containing 1% (v/v) protease inhibitor cocktail and 1% (v/v) phosphatase inhibitor cocktail (Nacalai Tesque, Kyoto, Japan), and then centrifuged at 800 g for 5 min at 4 °C. The supernatant was used as total cell lysate.
For Western blotting, proteins were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and then transferred to polyvinylidene di luoride membranes. Blotting membranes were blocked with TBS-T containing 5% (w/v) bovine serum albumin and subsequently reacted with antibodies against ADA (Santa Cruz Biotechnology) or -actin (Sigma, St Louis, MO, USA). After washing, membranes were reacted with a horseradish peroxidase-conjugated goat anti-rabbit IgG or goat anti-mouse IgG antibody. Immunoreactivity was detected with an ECL kit (GE Healthcare, Piscataway, NJ, USA) and visualized using a chemiluminescence detection system (GE Healthcare). Protein concentrations for each sample were determined with a BCA protein assay kit (Thermo Fisher Scienti ic).
Assay of extra-and intra-cellular adenosine
Nucleosides were extracted from cells or extracellular solutions by adding 2% trichloroacetic acid. After centrifugation at 5,000 g for 5 min at 4 °C, the supernatants were loaded onto a reversed phase highperformance liquid chromatography (HPLC)(LC-10ATvp; Shimadzu Co., Kyoto, Japan). An adenosine peak was detected at an absorbance of 260 nm (SPD-10Avp UV-VIS detector, Shimadzu Co.), and adenosine was quanti ied. 
Evaluation of tumor growth in mice inoculated with NCI-H2052 cells
Statistical analysis
Statistical analysis was carried out using unpaired t-test and Dunnett's test.
Results
EHNA induces apoptosis of cancer cells
For the MPM cell lines NCI-H28, NCI-H2052, NCI-H2452, and MSTO-211H cells, EHNA reduced cell viability in a concentration (0.01-1 mM)-and treatment time (24-48 h)-dependent manner, reaching below 20% of basal levels at 48-h treatment at 1 mM (Fig.  1A-D) . In the TUNEL staining, EHNA (1 mM) signi icantly increased the number of TUNEL-positive cells as compared with that for untreated control cells for all the investigated MPM cell lines (Fig. 1E-H) , indicating that EHNA induces apoptosis of MPM cells.
Likewise, EHNA reduced cell viability for the human lung cancer cell lines A549, SBC-3, and Lu-65 cells and the human hepatic cancer cell lines HepG2 and HuH-7 cells in a concentration (0.01-1 mM)-and treatment time (24-48 h)-dependent manner ( Fig.  2A-C,G,H) and de initely increased TUNEL-positive cells for these cell lines (Fig. 2D-F,I,J) . Taken together, these results indicate that EHNA has the potential to induce apoptosis of a variety of cancer cells.
Surprisingly, another ADA inhibitor pentostatin had no/little effect on cell viability for all the investigated MPM cell lines (Fig. 3A-D) .
EHNA increases intracellular adenosine concentrations in MPM cells
We next examined whether EHNA actually increases adenosine concentrations in MPM cells. Expectedly, EHNA (0.3 mM) increased intracellular adenosine concentrations in a treatment time (3-9 h)-dependent manner for all the investigated MPM cell lines, while extracellular adenosine concentrations were not increased or conversely decreased (Fig. 4A-D) .
Apoptosis of MPM cells is induced by knocking-down ADA
To ascertain whether EHNA-induced apoptosis of MPM cells is due to ADA inhibition, the ADA siRNA was constructed and transfected into cells. Expression of ADA protein for (Fig. 5A-D) , con irming ADA knock-down. Cell viability for NCI-H28, NCI-H2052, NCI-H2452, and MSTO-211H cells was signi icantly reduced by knocking-down ADA, and the effect was neutralized by the adenosine kinase inhibitor 4-amino-5-(3-bromophenyl)-7-(6-morpholino-pyridin-3-yl) pyrido[2,3-d] pyrimidine (ABT-702) (Fig. 6A-D) . Moreover, a signi icant increase in TUNELpositive cells was found for all the investigated MPM cell lines by knocking-down ADA ( Fig. 6E-H) . Collectively, these results suggest that EHNA increases intracellular adenosine concentrations by inhibiting ADA and that in turn, adenosine kinase-catalyzed conversion to AMP triggers apoptosis of MPM cells. 
Fig. 4. Effects of EHNA on extra-and intra-cellular adenosine concentrations. NCI-H28 (A), NCI-H2052 (B), NCI-H2452 (C), and MSTO-211H cells (D)
were treated with EHNA (0.3 mM) for 3-9 h, and then extra-and intracellular adenosine were quantiied by HPLC. In the graphs, each point represents the mean (± SEM) adenosine concentration (μM for extracellular adenosine, nmol/mg protein for intracellular adenosine)(n=4 independent experiments).
Fig. 5. ADA knockdown. NCI-H28 (A), NCI-H2052 (B), NCI-H2452 (C), and MS-TO-211H cells (D)
were transfected with the NC siRNA or the ADA siRNA followed by Western blotting 48 h after transfection. Signal intensities for ADA protein were normalized by those for -actin. In the graphs, each column represents the mean (± SEM) ADA protein intensity (n=4 independent experiments). P values, unpaired t-test. 
Discussion
A growing body of evidence has shown that high concentrations of extracellular adenosine is capable of inducing apoptosis in a variety of cancer cells mainly through intrinsic and/or extrinsic pathways [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] . ADA, an enzyme involved in purine metabolism, catalyzes the hydrolytic deamination of adenosine and 2'-deoxyadenosine to their corresponding hypoxanthine derivatives, inosine and 2'-deoxy-inosine. ADA inhibition, therefore, results in the accumulation of adenosine, 2'-deoxyadenosine, and 2'-deoxyATP in cells [21, 22] . Indeed, the ADA inhibitor EHNA increased intracellular adenosine concentrations in MPM cells. EHNA induced apoptosis in all the investigated MPM cell lines, human lung cancer cell lines, and human hepatic cancer cell lines. This suggests that an increase in intracellular adenosine concentrations due to ADA inhibition is essential for EHNA-induced apoptosis of MPM cells. In support of this idea, apoptosis of MPM cells was induced by knocking-down ADA. Notably, MPM cell death due to ADA knock-down was prevented by the adenosine kinase inhibitor ABT-702. This implies that AMP, produced by adenosine kinase-catalyzed phosphorylation of adenosine, following an increase in intracellular adenosine concentrations due to ADA inhibition is a key factor for EHNA-induced apoptosis of MPM cells. EHNA clearly suppressed tumor growth in mice inoculated with NCI-H2052 cells. Overall, these results indicate that EHNA could be a bene icial drug for treatment of MPM.
The most paradoxical result in the present study is that another ADA inhibitor pentostatin, whereas it increases intracellular adenosine concentrations, had no/little effect on cell viability for all the investigated MPM cell lines. This raises the possibility that EHNAinduced apoptosis of MPM cells may not be induced simply by raising intracellular adenosine levels due to ADA inhibition and that the unknown additional mechanism may participate in the EHNA action. Pentostatin in combination of 2'-deoxyadenosine is show to activate caspase-3 and induce apoptosis of human monocytoid leukemia cells [23] . Pentostatin, alternatively, has a striking cytotoxic effect on different types of T-cell lymphomas, including T-prolymphocytic leukemia, large granular lymphocyte leukemia, and hepatosplenic gd + T-cell lymphoma [24] . EHNA, on the other hands, acts as an inhibitor of cyclic nucleotide phosphodiesterase 2 (PDE2) as well as ADA [25] . Interestingly, PDE inhibitors could still induce cell death in a variety of cancer cells [26] [27] [28] . EHNA, accordingly, might exhibit an anticancer effect against MPM by inhibiting both ADA and PDE2. To answer this question, we are currently probing the target molecules responsible for EHNA-induced apoptosis of MPM cells.
Accumulating evidence has pointed that higher concentrations of adenosine induce apoptosis of a wide variety of cancer cells via intrinsic and extrinsic pathways [2] [3] [4] [5] [6] [7] [8] [9] [10] . This raises the possibility that adenosine is available for effective chemotherapy of cancers. Adenosine is an endogenous substance, and therefore, in use for chemotherapy less side effects are expected. From these points of view, EHNA, which induces MPM cell apoptosis by increasing endogenous adenosine concentrations, could be developed as a promising drug for MPM therapy. We are currently preparing for clinical challenge of ENHA.
In conclusion, the results of the present study clearly demonstrate that EHNA induces apoptosis of MPM cells and suppresses tumor growth in mice inoculated with NCI-H2052 cells. This may provide a new strategy for treatment of MPM.
